🇺🇸 Rivastigmine transdermal patch in United States

20 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bradykinesia — 2 reports (10%)
  2. Fibroma — 2 reports (10%)
  3. Gait Disturbance — 2 reports (10%)
  4. Hallucination — 2 reports (10%)
  5. Insomnia — 2 reports (10%)
  6. Mobility Decreased — 2 reports (10%)
  7. Muscle Rigidity — 2 reports (10%)
  8. On And Off Phenomenon — 2 reports (10%)
  9. Parkinson^S Disease — 2 reports (10%)
  10. Product Prescribing Error — 2 reports (10%)

Source database →

Other Neurology approved in United States

Frequently asked questions

Is Rivastigmine transdermal patch approved in United States?

Rivastigmine transdermal patch does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Rivastigmine transdermal patch in United States?

Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.